2009 Part D plan instructions
Final version of CMS "call letter" to potential Part D sponsors outlining requirements for the 2009 benefit year reiterates most of the drug-related policies set out in the draft version released in January (1"The Pink Sheet," Jan. 28, 2008, p. 27). To increase transparency on prior authorization requirements, the final call letter requires that sponsors compile such criteria in a standardized format and post it on plan Web sites. CMS will no longer allow plans to impose prior authorization requirements for Roche's HIV therapy Fuzeon (enfuvirtide), nor will the agency permit gap coverage to be limited to mail order drug purchases. In one change, CMS backs off the proposed requirement for electronic prescription reporting in 2009 and announces it will not make such reporting mandatory until 2010
You may also be interested in...
CMS is aiming to make Medicare Part D formulary prior authorization practices more clear and consistent by proposing new requirements for drug plans in its draft "call letter" to prospective plan sponsors for the 2009 benefit year
With India’s first and the world’s third mRNA vaccine, Gennova plans to provide access to its COVID-19 vaccine to those deprived of doses from Pfizer and Moderna. HDT Bio Corp’s suit in the US is not seen impacting marketing plans in India, COO tells Scrip
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.